An Israeli pharma company is testing an advanced compound that blocks a tumor’s blood supply. Used with standard chemo, it obliterates the growth.
Last year, about 44,000 Americans were diagnosed with pancreatic cancer, a notoriously resistant cancer to treat and the fourth most common cause of cancer-related death for men and women.
The prognosis for these patients could improve drastically if a compound developed by Israel’s Tiltan Pharma continues to succeed in clinical trials.
The compound, dubbed TL-118, comes from the labs of the Hebrew University of Jerusalem. It’s now undergoing its second phase of tests after proving effective against pancreatic tumors first in mice and then in more than 100 humans.
Chief operating officer Dan Goldstaub explains that the company’s approach is based on a relatively new understanding of how cancerous tumors grow. Through an abnormal process called angiogenesis, the tumors “recruit” blood vessels from neighboring tissue. Anti-angiogenic therapy is a revolutionary approach aimed at disrupting this process by blocking the tumor’s blood supply.
“Theoretically, we can treat all solid tumors this way,” Goldstaub tells ISRAEL21c. “However, some tumors are more susceptible to angiogenesis inhibition, and each tumor uses different mechanisms of angiogenesis.”
Several other drug developers have developed anti-angiogenic agents that block a single biological pathway. Tiltan’s approach is more aggressive. “Our product inhibits four different pathways, so even if we achieve mild inhibition on each pathway, the cumulative effect is broader,” says Goldstaub.
This breakthrough came out of a decade of research by Hebrew University-Hadassah Medical School Prof. Muli Ben-Sasson, scientific founder of Tiltan Pharma. Ben-Sasson worked for years with Judah Folkman, the Harvard professor who discovered the process of tumor angiogenesis.
“Dr. Ben-Sasson realized years ago what we now know for certain: that angiogenesis is too complex a mechanism to disrupt with a single agent,” says Goldstaub, “so he came up with the idea of taking a few agents and combining them together. He looked for components of the angiogenic process and searched for drugs already approved for other indications that might inhibit those mechanisms.”
After many attempts, Ben-Sasson hit upon the winning formula for TL-118. Based on preliminary results in animals and humans, Tiltan Pharma decided to test it specifically on people with pancreatic and prostate cancer.
Works together with standard chemo
In pre-clinical trials, TL-118 inhibited tumor growth significantly, compared to the standard-of-care chemotherapy. When it was combined with chemotherapy, it really packed a punch, abolishing the tumors completely in all treated animals.
Continue reading at:
By Abigail Klein Leichman